The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Valvular Heart Disease Treatment Market Research Report 2025
Synopsis
Valvular heart disease is characterized by damage to or a defect in one of the four heart valves namely the mitral valve, aortic valve, tricuspid valve, and pulmonary valve.
The global Valvular Heart Disease Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Valvular Heart Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Valvular Heart Disease Treatment.
Report Scope
The Valvular Heart Disease Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Valvular Heart Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Valvular Heart Disease Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
B. Braun Melsungen AG
Boston Scientific Corp.
Medtronic
CryoLife Inc.
Edwards Lifesciences Corporation
LivaNova PLC
Neovasc Inc.
Micro Interventional Devices
Symetis SA
Jenavalve Technology
TTK Healthcare Limited
Colibri Heart Valve
Lepu Medical Technology Co.
Braile Biomédica
Segment by Type
Cardiac Catheterization
Electrocardiogram (ECG)
Chest X-Ray
Stress Test
Others
Segment by Application
Hospital & Clinics
Ambulatory Surgical Centers
Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Valvular Heart Disease Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Valvular heart disease is characterized by damage to or a defect in one of the four heart valves namely the mitral valve, aortic valve, tricuspid valve, and pulmonary valve.
The global Valvular Heart Disease Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Valvular Heart Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Valvular Heart Disease Treatment.
Report Scope
The Valvular Heart Disease Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Valvular Heart Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Valvular Heart Disease Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
B. Braun Melsungen AG
Boston Scientific Corp.
Medtronic
CryoLife Inc.
Edwards Lifesciences Corporation
LivaNova PLC
Neovasc Inc.
Micro Interventional Devices
Symetis SA
Jenavalve Technology
TTK Healthcare Limited
Colibri Heart Valve
Lepu Medical Technology Co.
Braile Biomédica
Segment by Type
Cardiac Catheterization
Electrocardiogram (ECG)
Chest X-Ray
Stress Test
Others
Segment by Application
Hospital & Clinics
Ambulatory Surgical Centers
Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Valvular Heart Disease Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Valvular Heart Disease Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cardiac Catheterization
1.2.3 Electrocardiogram (ECG)
1.2.4 Chest X-Ray
1.2.5 Stress Test
1.2.6 Others
1.3 Market by Application
1.3.1 Global Valvular Heart Disease Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital & Clinics
1.3.3 Ambulatory Surgical Centers
1.3.4 Research Institutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Valvular Heart Disease Treatment Market Perspective (2019-2030)
2.2 Valvular Heart Disease Treatment Growth Trends by Region
2.2.1 Global Valvular Heart Disease Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Valvular Heart Disease Treatment Historic Market Size by Region (2019-2024)
2.2.3 Valvular Heart Disease Treatment Forecasted Market Size by Region (2025-2030)
2.3 Valvular Heart Disease Treatment Market Dynamics
2.3.1 Valvular Heart Disease Treatment Industry Trends
2.3.2 Valvular Heart Disease Treatment Market Drivers
2.3.3 Valvular Heart Disease Treatment Market Challenges
2.3.4 Valvular Heart Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Valvular Heart Disease Treatment Players by Revenue
3.1.1 Global Top Valvular Heart Disease Treatment Players by Revenue (2019-2024)
3.1.2 Global Valvular Heart Disease Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Valvular Heart Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Valvular Heart Disease Treatment Revenue
3.4 Global Valvular Heart Disease Treatment Market Concentration Ratio
3.4.1 Global Valvular Heart Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Valvular Heart Disease Treatment Revenue in 2023
3.5 Valvular Heart Disease Treatment Key Players Head office and Area Served
3.6 Key Players Valvular Heart Disease Treatment Product Solution and Service
3.7 Date of Enter into Valvular Heart Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Valvular Heart Disease Treatment Breakdown Data by Type
4.1 Global Valvular Heart Disease Treatment Historic Market Size by Type (2019-2024)
4.2 Global Valvular Heart Disease Treatment Forecasted Market Size by Type (2025-2030)
5 Valvular Heart Disease Treatment Breakdown Data by Application
5.1 Global Valvular Heart Disease Treatment Historic Market Size by Application (2019-2024)
5.2 Global Valvular Heart Disease Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Valvular Heart Disease Treatment Market Size (2019-2030)
6.2 North America Valvular Heart Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Valvular Heart Disease Treatment Market Size by Country (2019-2024)
6.4 North America Valvular Heart Disease Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Valvular Heart Disease Treatment Market Size (2019-2030)
7.2 Europe Valvular Heart Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Valvular Heart Disease Treatment Market Size by Country (2019-2024)
7.4 Europe Valvular Heart Disease Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Valvular Heart Disease Treatment Market Size (2019-2030)
8.2 Asia-Pacific Valvular Heart Disease Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Valvular Heart Disease Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Valvular Heart Disease Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Valvular Heart Disease Treatment Market Size (2019-2030)
9.2 Latin America Valvular Heart Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Valvular Heart Disease Treatment Market Size by Country (2019-2024)
9.4 Latin America Valvular Heart Disease Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Valvular Heart Disease Treatment Market Size (2019-2030)
10.2 Middle East & Africa Valvular Heart Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Valvular Heart Disease Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Valvular Heart Disease Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Valvular Heart Disease Treatment Introduction
11.1.4 Abbott Laboratories Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.1.5 Abbott Laboratories Recent Development
11.2 B. Braun Melsungen AG
11.2.1 B. Braun Melsungen AG Company Detail
11.2.2 B. Braun Melsungen AG Business Overview
11.2.3 B. Braun Melsungen AG Valvular Heart Disease Treatment Introduction
11.2.4 B. Braun Melsungen AG Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.2.5 B. Braun Melsungen AG Recent Development
11.3 Boston Scientific Corp.
11.3.1 Boston Scientific Corp. Company Detail
11.3.2 Boston Scientific Corp. Business Overview
11.3.3 Boston Scientific Corp. Valvular Heart Disease Treatment Introduction
11.3.4 Boston Scientific Corp. Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.3.5 Boston Scientific Corp. Recent Development
11.4 Medtronic
11.4.1 Medtronic Company Detail
11.4.2 Medtronic Business Overview
11.4.3 Medtronic Valvular Heart Disease Treatment Introduction
11.4.4 Medtronic Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.4.5 Medtronic Recent Development
11.5 CryoLife Inc.
11.5.1 CryoLife Inc. Company Detail
11.5.2 CryoLife Inc. Business Overview
11.5.3 CryoLife Inc. Valvular Heart Disease Treatment Introduction
11.5.4 CryoLife Inc. Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.5.5 CryoLife Inc. Recent Development
11.6 Edwards Lifesciences Corporation
11.6.1 Edwards Lifesciences Corporation Company Detail
11.6.2 Edwards Lifesciences Corporation Business Overview
11.6.3 Edwards Lifesciences Corporation Valvular Heart Disease Treatment Introduction
11.6.4 Edwards Lifesciences Corporation Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.6.5 Edwards Lifesciences Corporation Recent Development
11.7 LivaNova PLC
11.7.1 LivaNova PLC Company Detail
11.7.2 LivaNova PLC Business Overview
11.7.3 LivaNova PLC Valvular Heart Disease Treatment Introduction
11.7.4 LivaNova PLC Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.7.5 LivaNova PLC Recent Development
11.8 Neovasc Inc.
11.8.1 Neovasc Inc. Company Detail
11.8.2 Neovasc Inc. Business Overview
11.8.3 Neovasc Inc. Valvular Heart Disease Treatment Introduction
11.8.4 Neovasc Inc. Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.8.5 Neovasc Inc. Recent Development
11.9 Micro Interventional Devices
11.9.1 Micro Interventional Devices Company Detail
11.9.2 Micro Interventional Devices Business Overview
11.9.3 Micro Interventional Devices Valvular Heart Disease Treatment Introduction
11.9.4 Micro Interventional Devices Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.9.5 Micro Interventional Devices Recent Development
11.10 Symetis SA
11.10.1 Symetis SA Company Detail
11.10.2 Symetis SA Business Overview
11.10.3 Symetis SA Valvular Heart Disease Treatment Introduction
11.10.4 Symetis SA Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.10.5 Symetis SA Recent Development
11.11 Jenavalve Technology
11.11.1 Jenavalve Technology Company Detail
11.11.2 Jenavalve Technology Business Overview
11.11.3 Jenavalve Technology Valvular Heart Disease Treatment Introduction
11.11.4 Jenavalve Technology Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.11.5 Jenavalve Technology Recent Development
11.12 TTK Healthcare Limited
11.12.1 TTK Healthcare Limited Company Detail
11.12.2 TTK Healthcare Limited Business Overview
11.12.3 TTK Healthcare Limited Valvular Heart Disease Treatment Introduction
11.12.4 TTK Healthcare Limited Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.12.5 TTK Healthcare Limited Recent Development
11.13 Colibri Heart Valve
11.13.1 Colibri Heart Valve Company Detail
11.13.2 Colibri Heart Valve Business Overview
11.13.3 Colibri Heart Valve Valvular Heart Disease Treatment Introduction
11.13.4 Colibri Heart Valve Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.13.5 Colibri Heart Valve Recent Development
11.14 Lepu Medical Technology Co.
11.14.1 Lepu Medical Technology Co. Company Detail
11.14.2 Lepu Medical Technology Co. Business Overview
11.14.3 Lepu Medical Technology Co. Valvular Heart Disease Treatment Introduction
11.14.4 Lepu Medical Technology Co. Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.14.5 Lepu Medical Technology Co. Recent Development
11.15 Braile Biomédica
11.15.1 Braile Biomédica Company Detail
11.15.2 Braile Biomédica Business Overview
11.15.3 Braile Biomédica Valvular Heart Disease Treatment Introduction
11.15.4 Braile Biomédica Revenue in Valvular Heart Disease Treatment Business (2019-2024)
11.15.5 Braile Biomédica Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
